143 related articles for article (PubMed ID: 34847232)
1. Molecular, clinical, and prognostic implications of PTPN11 mutations in acute myeloid leukemia.
Fobare S; Kohlschmidt J; Ozer HG; Mrózek K; Nicolet D; Mims AS; Garzon R; Blachly JS; Orwick S; Carroll AJ; Stone RM; Wang ES; Kolitz JE; Powell BL; Oakes CC; Eisfeld AK; Hertlein E; Byrd JC
Blood Adv; 2022 Mar; 6(5):1371-1380. PubMed ID: 34847232
[TBL] [Abstract][Full Text] [Related]
2. PTPN11 mutations in adult acute myeloid leukaemia: Prevalence and clinical implications in the context of NPM1 mutation.
Liu J; Qin W; Wang B; Wang Z; Hua H; Zhou F; Jia Z; Wu P; Chao H; Lu X
Leuk Res; 2022 Jul; 118():106859. PubMed ID: 35617714
[TBL] [Abstract][Full Text] [Related]
3. A precision medicine classification for treatment of acute myeloid leukemia in older patients.
Mims AS; Kohlschmidt J; Borate U; Blachly JS; Orwick S; Eisfeld AK; Papaioannou D; Nicolet D; Mrόzek K; Stein E; Bhatnagar B; Stone RM; Kolitz JE; Wang ES; Powell BL; Burd A; Levine RL; Druker BJ; Bloomfield CD; Byrd JC
J Hematol Oncol; 2021 Jun; 14(1):96. PubMed ID: 34162404
[TBL] [Abstract][Full Text] [Related]
4. The Clinical impact of PTPN11 mutations in adults with acute myeloid leukemia.
Alfayez M; Issa GC; Patel KP; Wang F; Wang X; Short NJ; Cortes JE; Kadia T; Ravandi F; Pierce S; Assi R; Garcia-Manero G; DiNardo CD; Daver N; Pemmaraju N; Kantarjian H; Borthakur G
Leukemia; 2021 Mar; 35(3):691-700. PubMed ID: 32561839
[TBL] [Abstract][Full Text] [Related]
5. The clinical features and prognostic implications of PTPN11 mutation in adult patients with acute myeloid leukemia in China.
Yang J; Zhao L; Wu Y; Niu T; Gong Y; Chen X; Huang X; Liu J; Dai Y; Ma H
Cancer Med; 2023 Dec; 12(23):21111-21117. PubMed ID: 37937729
[TBL] [Abstract][Full Text] [Related]
6. Clinical characteristics and prognostic analysis of acute myeloid leukemia patients with PTPN11 mutations.
Sun Y; Zhang F; Huo L; Cai W; Wang Q; Wen L; Yan L; Shen H; Xu X; Chen S
Hematology; 2022 Dec; 27(1):1184-1190. PubMed ID: 36318614
[TBL] [Abstract][Full Text] [Related]
7. Prognostic Relevance of DNMT3A, FLT3 and NPM1 Mutations in Syrian Acute Myeloid Leukemia Patients.
Moualla Y; Moassass F; Al-Halbi B; Al-Achkar W; Georgeos M; Yazigi H; Khamis A
Asian Pac J Cancer Prev; 2022 Apr; 23(4):1387-1395. PubMed ID: 35485701
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Impact of Concurrent DNMT3A, FLT3 and NPM1 Gene Mutations in Acute Myeloid Leukemia Patients.
Elrhman HAEA; El-Meligui YM; Elalawi SM
Clin Lymphoma Myeloma Leuk; 2021 Dec; 21(12):e960-e969. PubMed ID: 34376373
[TBL] [Abstract][Full Text] [Related]
9. Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemia.
Stasik S; Eckardt JN; Kramer M; Röllig C; Krämer A; Scholl S; Hochhaus A; Crysandt M; Brümmendorf TH; Naumann R; Steffen B; Kunzmann V; Einsele H; Schaich M; Burchert A; Neubauer A; Schäfer-Eckart K; Schliemann C; Krause S; Herbst R; Hänel M; Frickhofen N; Noppeney R; Kaiser U; Baldus CD; Kaufmann M; Rácil Z; Platzbecker U; Berdel WE; Mayer J; Serve H; Müller-Tidow C; Ehninger G; Bornhäuser M; Schetelig J; Middeke JM; Thiede C;
Blood Adv; 2021 Sep; 5(17):3279-3289. PubMed ID: 34459887
[TBL] [Abstract][Full Text] [Related]
10. Genomic landscape of patients with FLT3-mutated acute myeloid leukemia (AML) treated within the CALGB 10603/RATIFY trial.
Jahn N; Jahn E; Saadati M; Bullinger L; Larson RA; Ottone T; Amadori S; Prior TW; Brandwein JM; Appelbaum FR; Medeiros BC; Tallman MS; Ehninger G; Heuser M; Ganser A; Pallaud C; Gathmann I; Krzykalla J; Benner A; Bloomfield CD; Thiede C; Stone RM; Döhner H; Döhner K
Leukemia; 2022 Sep; 36(9):2218-2227. PubMed ID: 35922444
[TBL] [Abstract][Full Text] [Related]
11. What Is Abnormal in Normal Karyotype Acute Myeloid Leukemia in Children? Analysis of the Mutational Landscape and Prognosis of the TARGET-AML Cohort.
Herlin MK; Yones SA; Kjeldsen E; Holmfeldt L; Hasle H
Genes (Basel); 2021 May; 12(6):. PubMed ID: 34064268
[TBL] [Abstract][Full Text] [Related]
12. [Association of Next Generation Sequencing Based Genotypic Profiling with MICM Characteristics in NPM1 Mutated Acute Myeloid Leukemia].
Wang B; Ling Y; Dai L; Gu WY; Zhang XW; Xing SS; Li HQ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Feb; 30(1):56-60. PubMed ID: 35123604
[TBL] [Abstract][Full Text] [Related]
13. Clinical Effect of Combined Mutations in DNMT3A, FLT3-ITD, and NPM1 Among Egyptian Acute Myeloid Leukemia Patients.
El Gammal MM; Ebid GT; Madney YM; Abo-Elazm OM; Kelany AK; Torra OS; Radich JP
Clin Lymphoma Myeloma Leuk; 2019 Jun; 19(6):e281-e290. PubMed ID: 30926392
[TBL] [Abstract][Full Text] [Related]
14. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
15. FMS-Like Tyrosine Kinase 3 (FLT3) and Nucleophosmin 1 (NPM1) in Iranian Adult Acute Myeloid Leukemia Patients with Normal Karyotypes: Mutation Status and Clinical and Laboratory Characteristics.
Rezaei N; Arandi N; Valibeigi B; Haghpanah S; Khansalar M; Ramzi M
Turk J Haematol; 2017 Dec; 34(4):300-306. PubMed ID: 28294102
[TBL] [Abstract][Full Text] [Related]
16. [Characterization of mutational pattern of patients with core-binding factor acute myeloid leukemia].
He J; Chao H; Zhou M; Lu X; Chen T; Yang J; Jiang N; Zhang R
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2019 Jul; 36(7):657-661. PubMed ID: 31302905
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of Coexisting Gene with NRAS in Acute Myeloid Leukemia].
Sheng YP; Hua HY; Chao HY; Zhu WY; Wang ZQ; Zhang Y; Zhou Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Apr; 30(2):351-356. PubMed ID: 35395962
[TBL] [Abstract][Full Text] [Related]
18. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study.
Paschka P; Marcucci G; Ruppert AS; Whitman SP; Mrózek K; Maharry K; Langer C; Baldus CD; Zhao W; Powell BL; Baer MR; Carroll AJ; Caligiuri MA; Kolitz JE; Larson RA; Bloomfield CD
J Clin Oncol; 2008 Oct; 26(28):4595-602. PubMed ID: 18559874
[TBL] [Abstract][Full Text] [Related]
19. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
20. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
